Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mateon Therapeutics Inc (MATN)

Mateon Therapeutics Inc (MATN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 23,462
  • Shares Outstanding, K 90,240
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,640 K
  • 60-Month Beta 1.33
  • Price/Sales 13.48
  • Price/Cash Flow N/A
  • Price/Book 1.47
Trade MATN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 04/05/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1900 +36.84%
on 03/19/21
0.3000 -13.33%
on 03/01/21
unch (unch)
since 02/26/21
3-Month
0.1900 +36.84%
on 03/19/21
0.3800 -31.58%
on 01/25/21
+0.0400 (+18.18%)
since 12/28/20
52-Week
0.1300 +100.00%
on 04/14/20
0.3800 -31.58%
on 01/25/21
+0.0910 (+53.85%)
since 03/27/20

Most Recent Stories

More News
MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS

AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phase...

MATN : 0.2600 (+8.33%)
MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT

MATN : 0.2600 (+8.33%)
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS

AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...

MATN : 0.2600 (+8.33%)
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM

AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...

MATN : 0.2600 (+8.33%)
MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™

AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) --   Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...

MATN : 0.2600 (+8.33%)
MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA

AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced...

MATN : 0.2600 (+8.33%)
MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™

AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announce...

MATN : 0.2600 (+8.33%)
MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT

AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced...

MATN : 0.2600 (+8.33%)
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC

AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive...

MATN : 0.2600 (+8.33%)
MATEON’S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT

-FPI FOR C001 PHASE 2 TRIAL AGAINST COVID-19

MATN : 0.2600 (+8.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting...

See More

Key Turning Points

3rd Resistance Point 0.3287
2nd Resistance Point 0.2993
1st Resistance Point 0.2797
Last Price 0.2600
1st Support Level 0.2307
2nd Support Level 0.2013
3rd Support Level 0.1817

See More

52-Week High 0.3800
Fibonacci 61.8% 0.2845
Last Price 0.2600
Fibonacci 50% 0.2550
Fibonacci 38.2% 0.2255
52-Week Low 0.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar